Lung Cancer

Despite recent therapeutic advances lung cancer remains the leading cause of cancer-related deaths worldwide. Our major interest lies in deciphering genomic heterogeneity and clonal evolution during the development and progression of lung cancer. Not only does this help us to better understand the variable clinical behavior of the disease but might also lead to the discovery of new therapeutic avenues.

To this end we are applying cutting-edge tumor cell enrichment strategies, next generation sequencing technologies and bioinformatics analysis on human tumor tissue specimens from our large biobank. Our tissue microarray resources and expertise in immunohistochemistry and fluorescence in-situ hybridization facilitate validation of individual biomarkers emerging from genomic profiling studies using “omics” technologies.